Navigation Links
BioMarin to Host Third Quarter 2010 Financial Results Conference Call and Webcast on Thursday, October 28 at 5:00 p.m. ET
Date:10/7/2010

NOVATO, Calif., Oct. 7 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 28, at 5:00 p.m. ET to discuss third quarter 2010 financial results.U.S. / Canada Dial-in Number:  866.202.3048International Dial-in Number:  617.213.8843Participant Code: 60493555Replay Dial-in Number: 888.286.8010Replay International Dial-in Number: 617.801.6888Replay Code: 45911037Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.

Contacts:InvestorsEugenia Shen BioMarin Pharmaceutical Inc. (415) 506-6570
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. BioMarin to Present at the Barclays Capital Global Healthcare Conference
2. BioMarins Chief Executive Jean-Jacques Bienaime to Receive Most Admired CEO Award From San Francisco Business Times
3. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
4. BioMarin to Present at the Morgan Stanley Healthcare Conference
5. BioMarin to Present at the Baird Healthcare Conference
6. BioMarin to Present at the Jefferies Healthcare Conference
7. BioMarin to Present at the Goldman Sachs Healthcare Conference
8. BioMarin to Present at the Deutsche Bank Health Care Conference
9. BioMarin to Present at the Baird Growth Stock Conference
10. BioMarin Announces First Quarter 2009 Financial Results
11. BioMarin to Host First Quarter 2009 Financial Results Conference Call and Webcast on Thursday, April 30 at 5:00 p.m. ET (23:00 CET)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... ... October 06, 2017 , ... ... Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers ... perform Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ...
(Date:10/6/2017)... ... October 06, 2017 , ... The HealthTech ... technology sector at their fourth annual Conference where founders, investors, innovative practitioners and ... the ELEVATE pitch competition showcasing early stage digital health and med tech companies. ...
(Date:10/5/2017)... YORBA LINDA, CA (PRWEB) , ... October 05, 2017 , ... ... tech innovators, engineers, and scientists from around the world, is giving back to cancer ... shirt sold in October. , Now through October 31, shoppers can use promo ...
(Date:10/5/2017)... ... October 05, 2017 , ... NIH ... of its Nanobind DNA/RNA extraction technology . Nanobind is a novel magnetic ... surface and that can be used for a wide variety of sample preparation ...
Breaking Biology Technology:
(Date:4/6/2017)... , April 6, 2017 ... RFID, ANPR, Document Readers, by End-Use (Transportation & Logistics, ... Facility, Oil, Gas & Fossil Generation Facility, Nuclear Power), ... Educational, Other) Are you looking for a ... sector? ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
Breaking Biology News(10 mins):